Revista medica de Chile · 2024
[Survival in Patients with Acute Myeloid Leukemia: A Survival Analysis of 120 Patients with Acute Myeloid Leukemia with a Focus on Patients Over 60 Years of Age at Sótero del Río Hospital].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Domínguez Ignacio, Naser Rodrigo, Abarca Marcelo
Аннотация
UNLABELLED: Acute myeloid leukemia (AML) is the most frequent type of leukemia in adults and has a high mortality burden. Patients over 60 years of age infrequently receive high-intensity chemotherapy.
AIM: To describe the clinical characteristics and evaluate the survival in patients with AML, focusing on patients over 60 years.
METHODS: A retrospective study of patients diagnosed and treated for non-promyelocytic AML at Sótero del Río Hospital in Santiago, Chile, between 2015 and 2022.
RESULTS: 120 patients with a median age at presentation of 57 years were included. 56% were male-overall survival was 19% at 3 years. The group treated with high-intensity chemotherapy had a survival chance of 35% at 3 years. Sixty-five patients were 60 years or older, of whom 15 received high-intensity chemotherapy with 20% survival at 3 years, which was significantly higher than the non-chemotherapy group, i.e., palliative care (46% vs. 5.2% at 1 year, p-value <0.001).
CONCLUSION: Results with chemotherapy in patients 60 years of age and above are good, but the proportion of patients treated in the age group was low compared to other national reports.
AIM: To describe the clinical characteristics and evaluate the survival in patients with AML, focusing on patients over 60 years.
METHODS: A retrospective study of patients diagnosed and treated for non-promyelocytic AML at Sótero del Río Hospital in Santiago, Chile, between 2015 and 2022.
RESULTS: 120 patients with a median age at presentation of 57 years were included. 56% were male-overall survival was 19% at 3 years. The group treated with high-intensity chemotherapy had a survival chance of 35% at 3 years. Sixty-five patients were 60 years or older, of whom 15 received high-intensity chemotherapy with 20% survival at 3 years, which was significantly higher than the non-chemotherapy group, i.e., palliative care (46% vs. 5.2% at 1 year, p-value <0.001).
CONCLUSION: Results with chemotherapy in patients 60 years of age and above are good, but the proportion of patients treated in the age group was low compared to other national reports.